Clinical Trials on Monomorphic Post-Transplant Lymphoproliferative Disorder in China

Total 1776 results

Peking University
University of Florida

Unknown

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Lymphomas

China, United States
Shanghai Simnova Biotechnology Co.,Ltd.
Wuhan Union Hospital, China

Recruiting

F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

China
Fujian Medical University

Unknown

Maintenance Therapy Post-HSCT in High-risk Aggressive Lymphoma

High-risk Aggressive Lymphoma After Auto-HSCT

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma

Lymphoma

China
Chinese PLA General Hospital

Unknown

Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

Primary Mediastinal Large B-cell Lymphoma

China
The Affiliated Hospital of the Chinese Academy...

Unknown

CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）

Leukemia, Lymphocytic, Acute

China
Shandong Lanjin Pharmaceuticals Co.,Ltd

Unknown

Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Neoplasms | Leukemia | Chronic Lymphocytic Leukemia

China
Chi Kong Li
Hong Kong Children's Hospital

Recruiting

Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

Leukemia, Lymphocytic | Lymphoma, Nonhodgkin

China
The First Affiliated Hospital of Soochow University
Zhongda Hospital; Suzhou Municipal Hospital; The First People's Hospital of Changzhou

Recruiting

Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL

Acute Lymphoblastic Leukemia

China
Second Affiliated Hospital, School of Medicine,...
First People's Hospital of Hangzhou; First Affiliated Hospital of Zhejiang... and other collaborators

Recruiting

Orelabrutinib and Sintilimab in Relapsed or Refractory Central Nervous System Lymphoma

Primary Central Nervous System Hodgkin Lymphoma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Refractory Indolent Adult Non-Hodgkin Lymphoma

China
Timmune Biotech Inc.
Hunan Provincial People's Hospital

Unknown

Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Leukemia | Non-Hodgkin Lymphoma of Intestine

China
Sun Yat-sen University

Unknown

Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Henan Cancer Hospital
The Beijing Pregene Science and Technology Company, Ltd.

Unknown

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

B Cell Lymphoma

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma

B-cell Lymphoma

China
Sun Yat-sen University

Recruiting

Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma

Lymphoma, Lymphoblastic

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

B-cell Lymphoma

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

CD19-targeting CAR T Cells for B Cell Lymphoma

B Cell Lymphoma

China
Shandong Provincial Hospital

Unknown

Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma

Lymphoma, Non-Hodgkin;Hodgkin Disease

China
First Affiliated Hospital of Zhejiang University

Unknown

Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma

China
jiangjingting

Unknown

Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma

Lymphoma, B Cell

China
Changzhou Jinyuan Pharmaceutical Manufacturing...
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:

Acute Lymphoblastic Leukemia

China
Peking University
Marino Biotechnology Co., Ltd.

Unknown

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Relapsed or Refractory B-cell Lymphoma

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Completed

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

China
Chinese PLA General Hospital

Recruiting

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell

China
Chinese PLA General Hospital

Recruiting

TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell

China
Chinese PLA General Hospital

Recruiting

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Advanced Solid Tumors | Relapsed/Refractory Non-Hodgkin Lymphoma

China
Chinese PLA General Hospital

Recruiting

Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma

Peripheral Blood Stem Cell Transplantation

China
Beijing Boren Hospital
Nanjing Legend Biotech Co.

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

T-cell Leukemia | T Cell Lymphoma

China
Ruijin Hospital

Unknown

Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Non-hodgkin Lymphoma,B Cell

China
Second Affiliated Hospital of Soochow University

Not yet recruiting

Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL

Lymphoma, Large B-Cell, Diffuse

China
Sun Yat-sen University

Recruiting

A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL

Pediatric Cancer | Anaplastic Lymphoma | MDD | MRD | Lymphoma, Nonhodgkin

China
Adagene (Suzhou) Limited

Terminated

Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Solid Tumor | Non Hodgkin Lymphoma

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT

Primary Central Nervous System Lymphoma | Conditioning | Autologous Hematopoietic Stem Cell Transplantation

China
Sun Yat-sen University

Terminated

P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens

Lymphoma, Extranodal NK-T-Cell

China
Sun Yat-sen University

Unknown

Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL

Lymphoma, Extranodal NK-T-Cell

China
Simcere Pharmaceutical Co., Ltd

Recruiting

Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients

Post-stroke Cognitive Impairment

China
Second Affiliated Hospital, School of Medicine,...
The First Affiliated Hospital of Nanchang University; RenJi Hospital; Ningbo... and other collaborators

Recruiting

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)

China
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

Relapsed or Refractory Multiple Myeloma

China
Institute of Hematology & Blood Diseases Hospital
MethylGene Tech Co., Ltd. China

Recruiting

ctDNA Methylation Sequencing for Myeloma

Multiple Myeloma

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Recruiting

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Relapsed or Refractory Multiple Myeloma

China
Xinhua Hospital, Shanghai Jiao Tong University...
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

Refractory or Relapsed Multiple Myeloma

China
Gracell Biotechnologies Ltd.

Recruiting

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...

Recruiting

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Multiple Myeloma

China
Sanofi

Completed

Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

China
Shenzhen Pregene Biopharma Co., Ltd.

Recruiting

Clinical Study of the Safety and Efficacy of BCMA CAR-NK

Multiple Myeloma | Immunotherapy

China
Ruijin Hospital

Recruiting

A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

Lymphoma | DLBCL | T Cell Lymphoma

China
Peking University People's Hospital
Qingdao Municipal Hospital

Recruiting

Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement (SPODUMENE)

Multiple Myeloma

China

Clinical Trials on Monomorphic Post-Transplant Lymphoproliferative Disorder in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations